Methylmalonic acidemia (MMA) is a rare inherited metabolic disorder in which the body cannot properly break down certain proteins and fats. It affects roughly 1 in 100,000 newborns worldwide. The core problem is a blocked step inside the mitochondria, the energy-producing centers of every cell, that causes toxic organic acids to build up in the blood, urine, and tissues.
How the Metabolic Block Works
When you digest protein, your body breaks it down into individual amino acids. Four of those amino acids (valine, isoleucine, methionine, and threonine), along with cholesterol and certain fats, follow a specific metabolic route that funnels them into the energy-producing cycle inside mitochondria. A key step in that route requires an enzyme called methylmalonyl-CoA mutase to convert one molecule (methylmalonyl-CoA) into another (succinyl-CoA) that can enter the energy cycle.
In MMA, that enzyme is either missing, barely functional, or lacks the helper molecule it needs to work. The helper molecule is a form of vitamin B12 called adenosylcobalamin. When the conversion stalls, methylmalonyl-CoA and its precursor, propionyl-CoA, pile up. These compounds and their byproducts, especially methylmalonic acid and propionic acid, accumulate throughout the body and interfere with multiple systems. They disrupt normal energy production in mitochondria, impair the liver’s ability to make glucose (contributing to dangerous drops in blood sugar), and interfere with the body’s ammonia-clearing system, leading to toxic ammonia buildup.
Genetic Subtypes
MMA is not a single genetic condition. Several different gene mutations can cause it, and the subtype matters because it influences severity and treatment options.
- mut0: The methylmalonyl-CoA mutase enzyme is completely absent. This is typically the most severe form.
- mut−: The enzyme is present but has significantly reduced activity. Symptoms are generally less severe than mut0 but still serious.
- cblA, cblB, cblD-MMA: The enzyme itself is normal, but the body cannot properly transport or convert vitamin B12 into the active cofactor the enzyme needs. These forms often respond to B12 supplementation.
- Epimerase deficiency: A defect in a different enzyme (methylmalonyl-CoA epimerase) that feeds into the same pathway. This is the rarest form.
Knowing the subtype guides treatment. Children with cobalamin-related forms (cblA, cblB) may see a dramatic reduction in toxic metabolites with B12 therapy, while those with mut0 will not respond to B12 at all.
Signs and Symptoms
In most cases, problems appear within the first days to months of life. A newborn with severe MMA may seem fine at birth but then develop poor feeding, vomiting, and increasing lethargy as toxic metabolites accumulate. Dehydration, weak muscle tone, and failure to gain weight are common early signs.
Milder forms may not become apparent until later in infancy or childhood, sometimes presenting as unexplained developmental delays, recurrent episodes of vomiting, or poor growth. In some cobalamin-related subtypes, symptoms can be subtle enough that the condition goes unrecognized for months or even years.
Metabolic Crises
One of the most dangerous aspects of MMA is the risk of metabolic crises, episodes where toxic metabolite levels spike suddenly. Common triggers include infections, fevers, fasting, surgery, or any physical stress that increases protein breakdown in the body. During a crisis, the body catabolizes its own muscle tissue for energy, flooding the blocked pathway with amino acids it cannot process.
A metabolic crisis can cause severe vomiting, extreme lethargy, rapid breathing, and in serious cases, coma. These episodes require emergency treatment focused on stopping protein breakdown, providing alternative energy sources, and clearing toxic metabolites. Even with prompt care, repeated crises can cause cumulative damage to the brain and other organs.
How MMA Is Detected
Most developed countries now screen for MMA through newborn blood spot testing. The screening measures levels of a compound called propionylcarnitine (C3) in the blood. Moderately elevated C3 levels (roughly 5 to 10 micromoles per liter, compared to a normal median around 1.65) raise suspicion for MMA. A second marker, methylmalonylcarnitine, helps distinguish MMA from other conditions that also raise C3.
When screening flags a potential case, confirmatory testing follows. This includes measuring methylmalonic acid levels in blood and urine, plasma amino acid analysis, and eventually genetic testing to identify the specific subtype. Genetic testing has become essential not just for confirming the diagnosis but for predicting B12 responsiveness and guiding long-term management.
Testing for B12 Responsiveness
All patients with newly diagnosed MMA should be tested for responsiveness to vitamin B12, since the cobalamin-related subtypes can be managed much more effectively with supplementation. The standard test involves measuring methylmalonic acid in the urine before and after receiving an injection of hydroxocobalamin (a form of B12). A reduction of more than 50% in methylmalonic acid output indicates the patient is B12-responsive.
This test must be done outside of a metabolic crisis and while the patient is not already receiving B12 treatment, so the results aren’t skewed. For those who do respond, ongoing hydroxocobalamin injections become a cornerstone of treatment.
Daily Management and Diet
The foundation of MMA management is controlling the intake of the four amino acids that feed into the blocked pathway: valine, isoleucine, methionine, and threonine. In practical terms, this means a diet carefully restricted in natural protein. Children with MMA eat measured amounts of regular food and supplement with special medical formulas that provide all other essential amino acids and nutrients without the problematic four.
Adequate calorie intake is critical. When the body doesn’t get enough energy from food, it starts breaking down its own protein for fuel, which feeds the toxic pathway. Avoiding prolonged fasting is a basic daily rule. Many families keep emergency protocols at home: high-calorie, low-protein drinks or foods they can give at the first sign of illness to prevent the body from entering a catabolic state. Carnitine supplementation is also commonly used to help the body clear accumulating organic acids.
Long-Term Complications
Even with careful management, MMA carries significant long-term risks. The two most common chronic complications are kidney disease and neurological deterioration. Chronic exposure to methylmalonic acid damages kidney tissue over time, and progressive kidney failure is one of the leading concerns in adolescents and adults with the condition, particularly in the mut0 subtype. Neurological complications range from developmental delays and intellectual disability to episodes of acute brain injury (metabolic stroke) during crises.
The mechanism behind these complications involves direct toxicity. Methylmalonic acid inhibits key enzymes in the mitochondrial energy chain, starving cells of energy. In the brain, it also disrupts ammonia clearance and alters how brain cells use alternative fuel sources like ketone bodies. This chronic energy failure in the kidneys and brain explains why these two organs bear the heaviest burden of the disease.
Organ Transplantation
For patients whose condition cannot be adequately controlled with diet and medication, organ transplantation is an option. It is not a cure but functions as a form of enzyme replacement: the transplanted organ provides working copies of the missing or defective enzyme.
For patients without significant kidney damage, liver transplantation alone may be considered. For those who already have kidney impairment, a combined liver and kidney transplant is the preferred approach. Kidney transplantation alone, even though it provides only a small amount of enzyme activity, can be enough to meaningfully improve metabolic balance in some patients.
Outcomes vary by approach. In a review of 167 MMA patients who received transplants, overall mortality was about 11%, though most individual studies reported 100% survival. The complication rate, however, was notable: roughly 49% of patients experienced at least one post-transplant complication. Patients who received only a liver transplant had the highest risk of continued metabolic crises, with some studies reporting recurrent decompensation in all liver-only recipients despite continued dietary restrictions and medication. In contrast, those who received kidney or combined liver-kidney transplants typically had no further metabolic crises.
Transplantation is generally reserved for patients who have exhausted other treatment options, and the decision requires weighing the surgical risks, including the possibility of progressive kidney or neurological damage even after transplant, against the burden of ongoing severe disease.